We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avery Dennison Closes Buyout of Smartrac's RFID Inlay Unit
Read MoreHide Full Article
Avery Dennison Corporation (AVY - Free Report) has closed the acquisition of Smartrac’s Transponder (RFID Inlay) Division, for a purchase price of €225 million ($248.4 million).
Smartrac is a leader in the development and manufacture of Radio-frequency identification (RFID) products. It has solid research and development capabilities, along with a proven track record for commercializing effective, high-value and high-quality RFID products.
Headquartered in Amsterdam, the Netherlands, Smartrac has production facilities in China, Malaysia, Germany and the United States. Its RFID transponder business has an attractive product portfolio for a wide range of customers.
Last November, Avery Dennison entered into an agreement to acquire Smartrac’s Transponder business. Through this acquisition, Avery Dennison will bolster its rapidly-growing Intelligent Labels platform across end markets and customers within the industrial and retail segments. The deal is likely to generate more than $450 million in revenues, with RFID business anticipated to grow 15-20% annually over the long term.
The transaction will back Avery Dennison’s strategy to invest organically, as well as through mergers and acquisitions, in order to shift its portfolio toward faster growing, higher value categories. In fact, the company expects the deal to be modestly dilutive to the current-year earnings.
Recently, Avery Dennison reported mixed fourth-quarter results, wherein earnings surpassed the Zacks Consensus Estimate, while sales missed the same. Both top- and bottom-line figures improved year over year.
For the current year, Avery Dennison expects adjusted EPS of $6.90-$7.15, up from the prior-year guidance of $6.45-$6.70, reflecting improved volume growth and continued productivity gains. The company continues to deliver stellar profit growth, margin expansion and double-digit adjusted EPS improvement backed by acquisitions, organic growth and strong presence in emerging markets.
Avery Dennison witnessed 1.5% organic revenue increase on growth in high-value categories and emerging markets, and volume improvement in the Label and Graphic Material (LGM) segment during the December-end quarter. The segment is well poised for growth in the ongoing year, on solid top-line performance and continued margin expansion, aided by growth in emerging markets, volume improvement, focus on high-value categories led by specialty labels, as well as contributions from productivity initiatives.
The company will benefit from its faster-growing high-value product categories, such as specialty labels and RFID. Continued strength in RFID and external embellishments will drive Retail Branding and Information Solutions sales, reflecting the ongoing penetration of apparel, as well as expansion in relatively newer verticals, including food, beauty and logistics. The segment is well poised to capture these opportunities with industry-leading innovation and manufacturing capabilities. Moreover, the company continues to increase its investments, in order to boost growth organically and through acquisitions with higher spending for business development and R&D.
Nevertheless, the company is bearing the brunt of sluggish market trends and currency headwinds. Due to the strengthening of the U.S. dollar, currency translation is expected to have a larger impact on Avery Dennison’s ongoing quarter’s results, while transition costs associated with the European restructuring might dent current-year margins.
Share Price Performance
Over the past year, Avery Dennison’s shares have gained 9.7%, outperforming the industry’s growth of 8.1%.
Zacks Rank & Key Picks
Avery Dennison currently carries a Zacks Rank #3 (Hold)
Northwest Pipe has an expected earnings growth rate of 19.5% for the current year. The stock has appreciated 34% over the past year.
Graco has a projected earnings growth rate of 4.3% for 2020. The company’s shares have rallied 19% over the past year.
Sharps Compliance has an estimated earnings growth rate of a whopping 767% for the ongoing year. In a year’s time, the company’s shares have gained 39%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Avery Dennison Closes Buyout of Smartrac's RFID Inlay Unit
Avery Dennison Corporation (AVY - Free Report) has closed the acquisition of Smartrac’s Transponder (RFID Inlay) Division, for a purchase price of €225 million ($248.4 million).
Smartrac is a leader in the development and manufacture of Radio-frequency identification (RFID) products. It has solid research and development capabilities, along with a proven track record for commercializing effective, high-value and high-quality RFID products.
Headquartered in Amsterdam, the Netherlands, Smartrac has production facilities in China, Malaysia, Germany and the United States. Its RFID transponder business has an attractive product portfolio for a wide range of customers.
Last November, Avery Dennison entered into an agreement to acquire Smartrac’s Transponder business. Through this acquisition, Avery Dennison will bolster its rapidly-growing Intelligent Labels platform across end markets and customers within the industrial and retail segments. The deal is likely to generate more than $450 million in revenues, with RFID business anticipated to grow 15-20% annually over the long term.
The transaction will back Avery Dennison’s strategy to invest organically, as well as through mergers and acquisitions, in order to shift its portfolio toward faster growing, higher value categories. In fact, the company expects the deal to be modestly dilutive to the current-year earnings.
Recently, Avery Dennison reported mixed fourth-quarter results, wherein earnings surpassed the Zacks Consensus Estimate, while sales missed the same. Both top- and bottom-line figures improved year over year.
For the current year, Avery Dennison expects adjusted EPS of $6.90-$7.15, up from the prior-year guidance of $6.45-$6.70, reflecting improved volume growth and continued productivity gains. The company continues to deliver stellar profit growth, margin expansion and double-digit adjusted EPS improvement backed by acquisitions, organic growth and strong presence in emerging markets.
Avery Dennison witnessed 1.5% organic revenue increase on growth in high-value categories and emerging markets, and volume improvement in the Label and Graphic Material (LGM) segment during the December-end quarter. The segment is well poised for growth in the ongoing year, on solid top-line performance and continued margin expansion, aided by growth in emerging markets, volume improvement, focus on high-value categories led by specialty labels, as well as contributions from productivity initiatives.
The company will benefit from its faster-growing high-value product categories, such as specialty labels and RFID. Continued strength in RFID and external embellishments will drive Retail Branding and Information Solutions sales, reflecting the ongoing penetration of apparel, as well as expansion in relatively newer verticals, including food, beauty and logistics. The segment is well poised to capture these opportunities with industry-leading innovation and manufacturing capabilities. Moreover, the company continues to increase its investments, in order to boost growth organically and through acquisitions with higher spending for business development and R&D.
Nevertheless, the company is bearing the brunt of sluggish market trends and currency headwinds. Due to the strengthening of the U.S. dollar, currency translation is expected to have a larger impact on Avery Dennison’s ongoing quarter’s results, while transition costs associated with the European restructuring might dent current-year margins.
Share Price Performance
Over the past year, Avery Dennison’s shares have gained 9.7%, outperforming the industry’s growth of 8.1%.
Zacks Rank & Key Picks
Avery Dennison currently carries a Zacks Rank #3 (Hold)
A few better-ranked stocks in the Industrial Products sector include Northwest Pipe Company (NWPX - Free Report) , Graco Inc. (GGG - Free Report) and Sharps Compliance Corp . All of these stocks sport a Zacks Rank #1 (Strong Buy), at present. You can see the complete list of today's Zacks #1 Rank stocks here.
Northwest Pipe has an expected earnings growth rate of 19.5% for the current year. The stock has appreciated 34% over the past year.
Graco has a projected earnings growth rate of 4.3% for 2020. The company’s shares have rallied 19% over the past year.
Sharps Compliance has an estimated earnings growth rate of a whopping 767% for the ongoing year. In a year’s time, the company’s shares have gained 39%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>